Description
Description: Lenshil contains lenvatinib, a tyrosine kinase inhibitor used primarily in the treatment of certain types of cancer.
Contents: Each capsule contains 4mg of lenvatinib.
Uses:
- Treatment of locally recurrent or metastatic thyroid cancer.
- Management of unresectable hepatocellular carcinoma (liver cancer) in combination with everolimus.
- Treatment of renal cell carcinoma (kidney cancer) in combination with other therapies.
How it Works: Lenvatinib inhibits multiple receptor tyrosine kinases involved in tumor growth and angiogenesis (the formation of new blood vessels), effectively blocking the oxygen and nutrient supply to cancer cells, which halts their growth.
Directions for Use: Taken orally once daily, with or without food. Dosage should be as prescribed by a healthcare provider.
Side Effects:
- Hypertension (high blood pressure)
- Fatigue
- Diarrhea
- Nausea
- Decreased appetite
- Weight loss
Precautions:
- Regular monitoring of blood pressure is necessary during treatment.
- Liver function tests should be performed periodically.
- Not recommended during pregnancy or breastfeeding due to potential risks to the fetus or infant.
There are no reviews yet.